page_title: Tezepelumab
hierarchical_section_title: Tezepelumab
caption_attribution_description: English: Crystal structure of human TSLP in complex with the Fab-fragment of the Tezepelumab antibody (PDB 5J13).
context_page_description: Tezepelumab is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis. It blocks thymic stromal lymphopoietin, an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.
  This drug is being developed in collaboration by MedImmune, LLC and Amgen.
  It is in Phase III trials as of October 2018.
  Structural studies by X-ray crystallography showed that Tezepelumab competes against a critical part of the TSLPR binding site on TSLP.
context_section_description: Tezepelumab (INN; development codes MEDI9929 and AMG 157) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis. It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.
  This drug is being developed in collaboration by MedImmune, LLC and Amgen.
  It is in Phase III trials as of October 2018.
  Structural studies by X-ray crystallography showed that Tezepelumab competes against a critical part of the TSLPR binding site on TSLP.
caption: Structural basis for inhibition of TSLP-signaling by Tezepelumab (PDB 5J13)[1]
exif: {}